GIOTRIF rPMS in Korean Patients With NSCLC

Afatinib Osimertinib Sequencing NIS

NCT03370770 ·Status: COMPLETED

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

NCT00770588 ·Status: COMPLETED ·Phase: PHASE4

Real World Data on Gi(l)Otrif® Dose Adjustment

NCT02751879 ·Status: COMPLETED

Third-line Treatment of Gefitinib in NSCLC Patients

NCT01933347 ·Status: COMPLETED ·Phase: PHASE2

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

NCT05920135 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

NCT00452244 ·Status: COMPLETED ·Phase: PHASE2

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

NCT04552535 ·Status: COMPLETED

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

NCT03455829 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

NCT01776684 ·Status: UNKNOWN ·Phase: NA

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

NCT04795245 ·Status: COMPLETED

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

NCT05394831 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

NCT05117658 ·Status: UNKNOWN ·Phase: PHASE2

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03122717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

NCT01588145 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

NCT01485809 ·Status: COMPLETED ·Phase: PHASE2

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

NCT03856697 ·Status: UNKNOWN ·Phase: PHASE3

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NCT02747953 ·Status: COMPLETED ·Phase: PHASE2

Afatinib Plus Nimotuzumb for NSCLC

NCT01861223 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

NCT03381066 ·Status: UNKNOWN ·Phase: PHASE3

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

NCT03399669 ·Status: UNKNOWN ·Phase: PHASE2

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

NCT05528458 ·Status: RECRUITING ·Phase: PHASE2

Selumetinib in Combination With Gefitinib in NSCLC Patients

NCT02025114 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

NCT02804776 ·Status: COMPLETED ·Phase: PHASE2

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

NCT06709859 ·Status: RECRUITING ·Phase: PHASE2

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00536107 ·Status: TERMINATED ·Phase: PHASE4